Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL457853 | 0.85 | CYP2A6 (0.47) | ERN1SMN1; SMN2TTKNPC1RAB9A | |
| SCHEMBL457871 | 0.84 | DHODH (0.44) | SMN1; SMN2NPC1RAB9AKDM4EL3MBTL1 | |
| SCHEMBL16712516 | 0.83 | ERN1 (0.42) | ERN1SMN1; SMN2TTKNPC1RAB9A | |
| SCHEMBL456610 | 0.82 | ERN1 (0.53) | ERN1SMN1; SMN2TTKL3MBTL1CYP11B1 | |
| SCHEMBL456882 | 0.81 | CYP2C9 (0.43) | ERN1SMN1; SMN2TTKCYP2C9CYP2A6 | |
| SCHEMBL457679 | 0.81 | ERN1 (0.40) | ERN1SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL458891 | 0.80 | PIK3CD (0.37) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL456449 | 0.79 | CYP2A6 (0.51) | ERN1SMN1; SMN2TTKNPC1RAB9A | |
| SCHEMBL29684066 | 0.78 | NPY5R (0.34) | NQO2ADORA2AADORA2BIRAK4MKNK1 | |
| SCHEMBL15363650 | 0.78 | NPY5R (0.34) | NQO2ADORA2AADORA2BIRAK4MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114573580-A | Crystalline forms of selegiline | UCB生物制药有限责任公司 | 2022-06-03 | — | — | CN | disclosed |
| US-11059820-B2 | Crystalline forms of seletalisib | UCB BIOPHARMA SPRL (BE) | 2021-07-13 | — | — | US | disclosed |
| EP-3630760-A1 | CRYSTALLINE FORMS OF SELETALISIB | UCB Biopharma SRL (BE) | 2020-04-08 | — | — | EP | disclosed |
| US-20200095246-A1 | CRYSTALLINE FORMS OF SELETALISIB | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2020-03-26 | — | — | US | disclosed |
| CN-110709399-A | Crystalline forms of selegiline | UCB生物制药私人有限公司 | 2020-01-17 | — | — | CN | disclosed |
| WO-2018219772-A1 | CRYSTALLINE FORMS OF SELETALISIB | UCB BIOPHARMA SPRL (BE) | 2018-12-06 | — | — | WO | disclosed |
| EP-2614061-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-9029392-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2015-05-12 | — | — | US | disclosed |
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-11-07 | — | — | US | disclosed |
| EP-2614061-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012032334-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095246-A1 | CRYSTALLINE FORMS OF SELETALISIB | BRAF, PI4KB, PI4K2B | ERN1 378/4885SMN1; SMN2 982/4885NQO2 3820/4885 |
| US-20130296338-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | MAP3K13, MAP4K3, MAP3K3 | ERN1 713/4885SMN1; SMN2 3681/4885NQO2 141/4885 |
| US-11059820-B2 | Crystalline forms of seletalisib | BRAF, PI4KB, PI4K2B | ERN1 378/4885SMN1; SMN2 982/4885NQO2 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.